Gencurix company News and Trends items

2trends

Posted on {{project.publicationDate}}

More information

{{#if project.autoTranslated}} {{{project.nameForDefaultLanguage}}} {{else}} {{{project.name}}} {{/if}}

{{/if}} {{{#if showDetailedInfos}}

(Statut : {{project.starRank}} {{project.publicationDate}})

Posted on 1/6/2020

Gencurix presented the research results on GenesWell BCT, a breast cancer prognostic test, in an international journal.

GenesWell BCT is a prognostic test that makes the prognosis of other cancer metastasis and recurrence within 10 years, by analyzing the expression levels of six cancer prognostic genes and three standard genes extracted from the RNA of cancer tissues removed during surgery of breast cancer patients. The study, led by Kyungpook National University Hospital, compared th...

More information

Gencurix can diagnose breast cancer through needle biopsy before surgery

Posted on 11/6/2019

A new study on Frontiers in Oncology comparing GenesWell(TM) BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast cancer

Molecular Diagnostics, GenesWell BCT, Breast Cancer, Prognostic Multigene Test, Clinical Study

More information

Gencurix's study explores GenesWell BCT and Oncotype DX differences

Gencurix company News and Trends items

Localization Map